Citations

Clear

626 citation(s) found for "Mehta, SH".

Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India
Mathew, Aju , Davis, Sissmol , Boby, Jeffrey Mathew , I, Anu R , Suryavanshi, Moushumi , Dawood, Shaheenah , Panda, Pankaj Kumar , Nag, Shona, Das, Arunangshu, Rohatgi, Nitesh, Shah, Riyaz , Thampy, Cherian, Mukherji, Deborah , Shilpakar, Ramila , Mullapally, Sujith Kumar, Popat, Sanjay , Parikh, Aparna Raj , Yadav, Siddhartha , Mehta, Prashant , Mukherji, Deborah , Shilpakar, Ramila , Mullapally, Sujith Kumar , Sirohi, Bhawna , Dawood, Shaheenah , Popat, Sanjay , Parikh, Aparna R. , Yadav, Siddhartha , Singh, Randeep K. , Sirohi, Bhawna

Mayo Clinic

JCO Global Oncology | March 14, 2024 | Volume: No volume available | Issue: 10 | Pages: No page available

10.1200/go.23.00330 | PMID 38484196 Get It

PURPOSE Accurate understanding of the genomic and transcriptomic data provided by next-generation sequencing (NGS) is essential for the effective utilization of precision oncology. Molecular tumor boards (MTBs) aim to translate the complex data in NGS reports into effective clinical interventions. Often, MTB treatment recommendations differ from those in the NGS reports. In this study, we analyze the discordance between these recommendations and the rationales behind the discordances, in a non–high-income setting, with international input to evaluate the necessity of MTB in clinical practice. METHODS We collated data from MTB that were virtually hosted in Chennai, India. We included patients with malignancies who had NGS reports on solid tissue or liquid biopsies, and excluded those with incomplete data. MTB forms and NGS reports of each clinical case were analyzed and evaluated for recommendation concordance. Concordance was defined as an agreement between the first recommendation in the MTB forms and the therapeutic recommendations suggested in the NGS report. Discordance was the absence of the said agreement. The rationales for discordance were identified and documented. RESULTS Seventy MTB reports were analyzed with 49 cases meeting the inclusion criteria. The recommendation discordance was 49% (24 of 49). Discordant recommendations were mainly due to low level of evidence for the drug (75% of cases). CONCLUSION The discordance between MTB and NGS vendor recommendations highlights the clinical utility of MTB. The educational experiences provided by this initiative are an example of how virtual academic collaborations can enhance patient care and provider education across geographic borders.
Institutional Variability in Anesthesia Time for Mehta Casting in Early-Onset Scoliosis (EOS)
Bonsignore-Opp, Lisa , Malka, Matan , Simhon, Matthew E. , Matsumoto, Hiroko , Sturm, Peter, Vitale, Michael G. , Group, On behalf of Pediatric Spine Study, Ball, Jacob R. , Pahys, Joshua M. , Larson, A. Noelle , Roye, Benjamin D. , Group, On behalf of Pediatric Spine Study

Mayo Clinic

Journal of Pediatric Orthopaedics | February 14, 2024 | Volume: 44 | Issue: 5 | Pages: 297-302

10.1097/bpo.0000000000002644 | PMID 38353100 Get It

Purpose: Mehta casting is a potentially curative intervention for early-onset scoliosis (EOS) that typically requires multiple anesthetics. The Food and Drug Administration (FDA) reported that >3 hours of anesthesia under the age of 3 years old may alter brain development; however, no standard exists for the duration of anesthesia during casting. The purpose of this study is to quantify the variability in anesthesia during Mehta casting. We hypothesize that significant institutional variability exists and may be attributed to modifiable factors. Methods: An EOS registry was used to identify patients who underwent at least one Mehta casting procedure. Anesthesia exposure was quantified, and site variability was assessed by patient characteristics, cast placement, procedure type, and equipment used. Results: Our cohort consisted of 208 patients from 5 institutions (age 2.6±1.4 y). There were 1097 Mehta casting procedures, with 5.4±3.6 castings per patient. Of these patients, 106 (51%) were female, with an average age of 2.11±1.29 years old at the time casting was initiated. Patient etiologies included 154 idiopathic (74.0%), 22 syndromic (10.6%), 18 congenital (8.7%), 11 neuromuscular (5.3%), and 3 unknown (1.4%). Anesthesia time was 69±31 minutes and varied significantly between sites (59±14 to 117±46 min; P<0.001). Cumulative anesthesia time for patients under 3 years was 320±197 minutes with 120/161 (74.5%) patients exceeding 3 hours. Anesthesia time was lower after the FDA warning in 2016 compared with pre-2016 (71±30 vs. 66±32, P=0.008). Conclusions: Patients undergoing Mehta casting are at significant risk of exceeding 3 hours of anesthesia, which the FDA has stated may be harmful for children <3 years. Significant site variability indicates that standardization protocols should be developed to encourage best practices and minimize anesthetic times. Level of Evidence: Prognostic Level II.
Clinical Utility and Diagnostic Yield of Genetic Testing for Inherited Neuromuscular Disorders in a Single, Large Neuromuscular Center
Ebert, Suzahn E. , Meiling, James B. , Caress, James B. , Gandhi, Rachana , Penry, Vanessa Baute , Puwanant, Araya , Cartwright, Michael S. , Gandhi Mehta, Rachana K , Baute Penry, Vanessa , Meiling, James B

Mayo Clinic

Neurology Clinical Practice | February 1, 2024 | Volume: 14 | Issue: 2 | Pages: No page available

10.1212/cpj.0000000000200268 | PMID 38585444 Get It

Evaluating the sensitivity of EQ-5D-5L in patients with brain metastases: a secondary analysis of NRG CC001
Cherng, H.R.R. , Qu, Melody, Zafarí, Zafar , Armstrong, Terri S. , Gondi, Vinai , Brown, Paul D. , Mishra, Mark V. , Qu, Xuanlu , Cherng, Hua-Ren R , Armstrong, Terri S , Mishra, Mark V , Bentzen, Søren M. , Mehta, Minesh P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 28, 2024 | Volume: 116 | Issue: 6 | Pages: 983-989

10.1093/jnci/djae020 | PMID 38281073 Get It

Abstract Background EuroQoL EQ-5D-5L is a commonly used measure of health-related quality of life in clinical trials given the use of its index score as a measure of health utilities. It is unclear whether EQ-5D-5L is sensitive to changes in neurocognitive function and progression that occur following brain radiation. This study sought to evaluate the sensitivity of EQ-5D-5L in reflecting these changes. Methods A secondary analysis of NRG Oncology CC001 was performed. Mean EQ-5D-5L index and visual analog scale (VAS) score changes from baseline between groups of patients stratified by neurocognitive function and intracranial progression status were assessed. MD Anderson Symptom Inventory for brain tumor (MDASI-BT) symptom and interference items were also analyzed between groups. Results EQ-5D-5L mean index and VAS score changes between patients who had cognitive failure and those who had preserved cognition showed no statistically significant differences at any timepoint. In contrast, VAS changes at 4 months (1.61 vs -5.13, P = .05) and 6 months (8.17 vs −0.14, P = .04) were significantly improved in the patients who survived without intracranial progression. MDASI-BT cognitive factor scores were improved in the cohort of patients with preserved neurocognitive function at 2 months (1.68 vs 2.08, P = .05) and 4 months (1.35 vs 1.83, P = .04). MDASI-BT symptom interference was significantly associated with intracranial progression at 4 months, but not with neurocognitive status. Conclusion EQ-5D-5L index and VAS scores were not sensitive to neurocognitive changes that patients experienced, but VAS scores were sensitive to progression. This study challenges the routine use of EQ-5D as a quality of life metric in brain metastases clinical trials that are focused on preventing neurocognitive dysfunction. Trial Registration NCT# 02360215.
Mis-spliced transcripts generate de novo proteins in TDP-43–related ALS/FTD
Seddighi, Sahba , Qi, Yue , Brown, Anna‐Leigh , Wilkins, Oscar G. , Bereda, Colleen , Belair, Cédric , Zhang, Yong‐Jie , Prudencio, Mercedes , Keuss, Matthew J. , Khandeshi, Aditya J , Pickles, Sarah , Hill, Sarah E. , Hawrot, James , Ramos, Daniel M. , Roberts, Jessica P. , Sacramento, Erika Kelmer , Shah, Syed Islamuddin , Nalls, Mike A., Colon, J , Reyes, Joel F. , Ryan, Veronica H. , Nelson, Matthew P. , Cook, Casey , Screven, Laurel A. , Kwan, Justin , Mehta, Puja R. , Zanovello, Matteo , Shantaraman, Anantharaman , Ping, Lingyan , Koike, Yuka , Oskarsson, Björn , Staff, Nathan P. , Ahmed, Aisha , Ule, Jernej , Jacobson, Steven , Reich, Daniel S. , Rohrer, Jonathan D. , Malaspina, Andrea , Glass, Jonathan D. , Seyfried, Nicholas T., Maragkakis, Manolis , Petrucelli, Leonard , Fratta, Pietro , Ward, Michael E. , Fratta, Pietro , Qi, Yue A , Khandeshi, Aditya , Yuan, Hebao , Roberts, Jessica , Sacramento, Erika Kelmer , Shah, Syed I , Colón-Mercado, Jennifer M , Reyes, Joel F , Ryan, Veronica H , Cook, Casey N , Li, Ziyi , Screven, Laurel , Mehta, Puja R , Zanovello, Matteo , Hallegger, Martina , Shantaraman, Anantharaman , Ping, Lingyan , Koike, Yuka , Oskarsson, Björn , Staff, Nathan P , Duong, Duc M , Ahmed, Aisha , Secrier, Maria , Ule, Jernej , Jacobson, Steven , Reich, Daniel S , Rohrer, Jonathan D , Dickson, Dennis W , Glass, Jonathan D , Seyfried, Nicholas T , Maragkakis, Manolis , Petrucelli, Leonard , Fratta, Pietro , Ward, Michael E , Zhang, Yong-Jie , Prudencio, Mercedes , Bereda, Colleen , Fratta, Pietro , Li, Ziyi , Dickson, Dennis W. , Ori‬‬, Alessandro , Seyfried, Nicholas T.

Mayo Clinic

Science Translational Medicine | January 26, 2024 | Volume: 16 | Issue: 734 | Pages: No page available

10.1126/scitranslmed.adg7162 | PMID 38277467 Get It

Functional loss of TDP-43, an RNA binding protein genetically and pathologically linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), leads to the inclusion of cryptic exons in hundreds of transcripts during disease. Cryptic exons can promote the degradation of affected transcripts, deleteriously altering cellular function through loss-of-function mechanisms. Here, we show that mRNA transcripts harboring cryptic exons generated de novo proteins in TDP-43–depleted human iPSC–derived neurons in vitro, and de novo peptides were found in cerebrospinal fluid (CSF) samples from patients with ALS or FTD. Using coordinated transcriptomic and proteomic studies of TDP-43–depleted human iPSC–derived neurons, we identified 65 peptides that mapped to 12 cryptic exons. Cryptic exons identified in TDP-43–depleted human iPSC–derived neurons were predictive of cryptic exons expressed in postmortem brain tissue from patients with TDP-43 proteinopathy. These cryptic exons produced transcript variants that generated de novo proteins. We found that the inclusion of cryptic peptide sequences in proteins altered their interactions with other proteins, thereby likely altering their function. Last, we showed that 18 de novo peptides across 13 genes were present in CSF samples from patients with ALS/FTD spectrum disorders. The demonstration of cryptic exon translation suggests new mechanisms for ALS/FTD pathophysiology downstream of TDP-43 dysfunction and may provide a potential strategy to assay TDP-43 function in patient CSF.
CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial.
Kelly, Ronan J. , Jia, Jie , Baffa, Raffaele, Kim, Dae Won , Yoon, Harry H. , Botta, Gregory P. , Jin, Zhaohui , Ma, Hong, Ku, Geoffrey , Zhao, Dan , Mehta, Rutika Jitesh , Carnevale, Julia C. , Sierra, Gloria , Li, Zhonghai

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: 356-356

10.1200/jco.2024.42.3_suppl.356 Get It

356 Background: Autologous anti-claudin 18.2 (CLDN18.2) CAR T cell, satricabtagene autoleucel (satri-cel), was developed to treat solid tumors. We report the completed results of the Phase 1b ELIMYN18.2 study (Cohort A) in gastric/gastroesophageal junction (GC/GEJ) and pancreatic cancer (PC). Methods: This single-arm, open-label, Phase 1b/2 study (NCT04404595) evaluated the safety and efficacy of satri-cel in patients with CLDN18.2-positive advanced GC/GEJ or PC. Cohort A consisted of a modified 3+3 design. After a conditioning regimen of fludarabine, cyclophosphamide, and nab-paclitaxel, patients were administered 1-3 cycles of satri-cel. The primary objectives were safety and determination of the recommended Phase 2 dose (RP2D). Adverse Events (AEs) were graded per CTCAE 5.0, objective response rate (ORR), and clinical benefit rate (CBR) including CR, PR, and ≥6-month SD were assessed by the investigator per RECIST 1.1. Results: As of May 14, 2023, twenty-four patients underwent leukapheresis in Cohort A. Nineteen patients (7 GC/GEJ and 12 PC) with a median of 3 (range: 1-8) prior therapeutic lines had satri-cel at three dose levels (DLs) between 250×106 and 600×106 cells. Seven patients received a 2nd dose and two patients received a 3rd dose of satri-cel at a median of 113 and 259 days, respectively, post-first infusion. All 19 patients experienced at least one AE. No DLTs occurred and 17 patients experienced cytokine release syndrome (CRS). Two cases of Grade 3 CRS were reported, and all other CRS were Grade 1 or 2. Two Grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred. All CRS and ICANS were resolved. No severe gastrointestinal-related AEs were found. No increased toxicities were reported after any reinfusion. No satri-cel treatment-related death occurred. For all patients, the best ORR was 26.3%, the median DOR was 3.7 months and the CBR was 42.1%. The median PFS was 5.2 months, and overall survival was 12.8 months (95% CI 5.7-NE) after leukapheresis, and the median PFS was 3.3 months, and overall survival was 8.9 months (95% CI 3.3-NE) after the first infusion. In the GC/GEJ group, the ORR was 42.9% (3/7), the median DOR was 6.9 months and the CBR was 57.1%. In the PC group, the ORR was 16.7% (2/12), the median DOR was 3.4 months and the CBR was 33.3%. An ORR of 42.9% (3/7) and a CBR of 71.4% were reported at the DL3 of 600×106 cells which was selected as RP2D. At DL3, one GC patient achieved a CR and two PC patients had PR, suggesting the PC group achieved an ORR of 40% (2/5) and the GC group achieved an ORR of 50% (1/2). In addition, tumor shrinkage was detected in 73.7 % (14/19) of patients. Conclusions: The safety profile and therapeutic efficacy of satri-cel were shown to be promising in heavily pretreated patients with CLDN18.2-positive advanced GC/GEJ and PC . In the Phase 2 study, the first patient with GC received satri-cel in May 2023. Clinical trial information: NCT04404595 .
Practice Readiness? Trends in Chief Resident Year Training Experience Across 13 Residency Programs
Corey, Zachary , Lehman, Erik , Lemack, Gary E. , Clifton, Marisa , Atiemo, Humphrey , Sorensen, Mathew D., Smith, Ryan P. , Buckley, Jill C. , Thompson, Houston, Badalato, Gina M., Wallen, Eric, Klausner, Adam P. , Mehta, Akanksha , Lee, Richard S. , Breyer, Benjamin N. , Raman, Jay D.

Mayo Clinic

Urology Practice | December 29, 2023 | Volume: 11 | Issue: 2 | Pages: 430-438

10.1097/upj.0000000000000494 | PMID 38156717 Get It

Addressing diagnostic dilemmas in eosinophilic esophagitis using esophageal epithelial eosinophil‐derived neurotoxin
Thomas, Jessina, Hopson, Puanani , Deb, Chirajyoti , Bornstein, Jeffrey D. , Mehta, Devendra I. , Bittar, Khaled, Smadi, Yamen

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | December 27, 2023 | Volume: 78 | Issue: 2 | Pages: 304-312

10.1002/jpn3.12054 | PMID 38374551 Get It

AbstractObjectivesEosinophil‐derived neurotoxin (EDN) is a viable marker of eosinophilic esophagitis (EoE) disease activity. We studied the utility of measuring EDN from esophageal epithelial brushings for diagnosing EoE, focusing on two scenarios: (1) cases of exclusive distal eosinophilia and (2) cases of discrepancy between endoscopy and histology.MethodsRecords of patients who underwent esophagogastroduodenoscopy (EGD) with EDN measured via esophageal brushings at Arnold Palmer Hospital for Children in Orlando, Florida from January 2014 to October 2018 were retrospectively reviewed. Demographics, clinical, endoscopic, and histologic data were collected.ResultsWe reviewed 231 patient records (66.7% male, mean age 10.3 years, range 1–22 years). EDN values correlated with endoscopic reference score (EREFS) and peak eosinophil count (PEC) (Spearman's rho = 0.756 (p < 0.001) and 0.824 (p < 0.001) respectively). Average PEC, EREFS, and EDN concentrations were higher in patients with active EoE than in controls or patients with EoE in remission (inactive). When grouping patients based on esophageal eosinophilia distribution, EDN mirrored PEC, and EREFS. Patients with exclusive distal eosinophilia had lower EDN concentrations than those with eosinophilia in >1 level of the esophagus (23.8 ± 46.1 mcg/mL vs. 171.3 ± 205.8 mcg/mL respectively, p < 0.001). EDN values were more consistent with EREFS in cases of discrepancies between endoscopic findings and pathology (p < 0.001).ConclusionEDN measured in esophageal brushing samples reflects disease activity objectively and accurately. It also offers significant value in cases of exclusive distal esophageal eosinophilia and when discrepancies exist between endoscopy and histology.
Associations between neuropsychiatric symptoms, pathology in neuropathological cohorts of Alzheimer’s disease, Alzheimer’s disease with Lewy bodies and Dementia with Lewy bodies
Shakir, Neha , Belden, Christine M. , Mehta, Shyamal H. , Shill, Holly A. , Driver‐Dunckley, Erika, Beach, Thomas G. , Tremblay, Cécilia , Zhang, Nan , Adler, Charles H. , Driver‐Dunckley, Erika , Serrano, Geidy E. , Atri, Alireza , Choudhury, Parichita

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S18 | Pages: No page available

10.1002/alz.079470 Get It

AbstractBackgroundNeuropsychiatric symptoms (NPS) are frequent in Alzheimer’s Disease dementia (ADD) but a higher NPS burden is found in dementia with Lewy bodies (DLB). Lewy body (LB) pathology frequently co‐occurs with AD pathology and may not meet neuropathological criteria for DLB (ADLB). Previous studies have shown that both ADLB and DLB cases have faster cognitive and/or functional decline compared to AD. However, the differences in NPS severity over disease course and survival in these pathologic subgroups is not well understood.MethodCases from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) with a final neuropathologic diagnosis of DLB (±AD co‐pathology; n = 65), ADLB (n = 89), AD (without LB) (n = 140), and controls (no neuropathological diagnosis) (n = 82) were included. Total NPI‐Q (scores ranging from 0‐36) at time of enrollment and within 2.5 years of death were calculated for all groups. Statistical analysis utilizing ANCOVA (adjusting for age, sex, baseline MMSE and cognitive symptom duration) with pairwise comparisons, and Kaplan‐Meier curves were completed.ResultAge at onset of cognitive symptoms was not different between pathology groups. NPI‐Q scores at enrollment were highest in ADLB (7.33 ± 4.85), and higher (p<0.001) than DLB (5.10 ± 3.37), AD (4.54 ± 3.63) and controls (1.78 ± 1.70). At final evaluation, NPI‐Q scores were highest in DLB (10.04 ± 6.28), followed by ADLB (8.0 ± 4.), and ADD (7.61 ± 5.05) when compared to controls (2.78 ± 3.97) (all p<0.001). DLB and AD demonstrated significant increases in NPI‐Q severity during follow up (p < 0.001). AD had longer survival time (5.8 years) compared to ADLB (4.0 years) and DLB (3.9 years). Subjects with NPS had a shorter median survival time (3.4 years) compared to subjects without NPS (6.5 years; p = 0.002).ConclusionA higher NPS burden and shorter survival is seen in both DLB and ADLB, as compared with AD. This suggests that diffuse neocortical LB pathology is not the major driver of either NPS or survival.
Decline in cognitive trajectories in the neuropathological spectrum of Lewy Body disease
Choi, Alexander S., Belden, Christine M. , Mehta, Shyamal H. , Driver‐Dunckley, Erika, Shill, Holly A. , Beach, Thomas G. , Choudhury, Parichita , Zhang, Nan , Boeve, Bradley F. , Tremblay, Cécilia , Choi, Alexander, Driver‐Dunckley, Erika , Shprecher, David , Serrano, Geidy E. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S18 | Pages: No page available

10.1002/alz.079086 Get It

AbstractBackgroundPathological Lewy body disease (LBD) may commonly present clinically as Parkinson’s disease dementia (PDD), Dementia with Lewy bodies (DLB) or Alzheimer’s disease dementia (ADD). Neuropathological definitions also include a group in which ADD is present, but the postmortem Lewy pathology does not meet threshold density and distribution levels for the neuropathological diagnosis of DLB (ADLB). Little is known about the cognitive profiles of patients with ADLB and despite common underlying pathology, studies delineating neuropsychological profiles in LBD are fraught with inconsistencies. We characterized the longitudinal cognitive trajectories defined by neuropsychological profiles in cases along the pathological spectrum of LBD.MethodCases from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) with a cognitive diagnosis of dementia at death and who at minimum, had two neuropsychological evaluations were included. Final neuropathological diagnosis was determined as LBD (neocortical or limbic LB ± AD), ADLB, and AD pathology only. LBD cases were categorized by their cognitive clinical syndromes as PDD and DLB. Global cognition was evaluated using MMSE. Neuropsychological domains of Memory, Executive function, language, attention, and visuospatial were evaluated. Mixed linear methods were used to predict longitudinal change for a given baseline MMSE.Result287 participants and 1874 participant‐years of data were included in this study. LBD (n = 115), and ADLB (52) groups were predominantly male, while AD (n = 114) group was primarily female. Baseline MMSE was similar across all pathologic groups. Linear mixed modelling methods showed faster decrease in memory domain scores (decreasing 0.22 units/year – 0.42 units/year faster, p = 0.01) in ADLB group compared to other groups. Significantly faster decline was noted in LBD and ADLB group in clock drawing (p<0.001), fluency scores (declining 1.02 unit/year faster p<0.001) compared to AD group. There was no difference between PDD and DLB clinical subgroups.ConclusionIn autopsy confirmed cases, ADLB had an accelerated trajectory of decline in memory tasks, while AD, and LBD appeared to have similar trajectories. In contrast, all groups with Lewy bodies progressed faster and showed accelerated decline compared to AD in measures of frontal‐subcortical functions. These results may inform antemortem classification of patients and diagnostic accuracy in these groups.